<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00406991</url>
  </required_header>
  <id_info>
    <org_study_id>2002-015</org_study_id>
    <secondary_id>2003P-000224</secondary_id>
    <secondary_id>EY014812</secondary_id>
    <nct_id>NCT00406991</nct_id>
  </id_info>
  <brief_title>Retinal Blood Flow and Microthrombi in Type 1 Diabetes</brief_title>
  <official_title>Retinal Blood Flow and Microthrombi in Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Schepens Eye Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts Eye and Ear Infirmary</source>
  <brief_summary>
    <textblock>
      The project aims to find mechanisms for the abnormal retinal blood flow that in diabetic&#xD;
      patients often precedes any evidence of clinical retinopathy and may contribute to the&#xD;
      development of retinopathy.&#xD;
&#xD;
      Specifically, the projects tests the hypothesis that reduced retinal blood flow found in&#xD;
      young patients with type 1 diabetes reflects increased resistance in the small vessels of the&#xD;
      retina caused by the formation of small blood clots, called microthrombi; and that&#xD;
      antiplatelet agents normalize the reduced retinal blood flow.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ultimate goal of this research is to contribute to the development of strategies to&#xD;
      prevent diabetic retinopathy. This project will test the hypothesis that antiplatelet agents&#xD;
      normalize the reduced blood flow observed early in the course of type 1 diabetes. If the&#xD;
      hypothesis is proven correct, the results will indicate that the formation of small blood&#xD;
      clots (microthrombi) occurs early in diabetic retinal vessels. In turn, because&#xD;
      microthrombosis could readily account for the occlusive microangiopathy that causes the&#xD;
      sight-threatening stages of diabetic retinopathy, the results will propose the desirability&#xD;
      of antiplatelet therapy for the prevention of diabetic retinopathy.&#xD;
&#xD;
      We have three specific aims:&#xD;
&#xD;
        1. To confirm that, under basal conditions, retinal blood flow measured with the laser&#xD;
           Doppler method in a group of type 1 diabetic patients with no or minimal retinopathy&#xD;
           differs from the flow measured in age- and sex-matched nondiabetic control subjects;&#xD;
&#xD;
        2. To determine whether the response of retinal blood flow to low-dose aspirin (81 mg/day)&#xD;
           administered for 2 months versus placebo, differs between type 1 diabetic patients with&#xD;
           no or minimal retinopathy and age- and sex-matched nondiabetic control subjects;&#xD;
&#xD;
        3. To determine whether in type 1 diabetic patients with no or minimal retinopathy the&#xD;
           response of retinal blood flow to low-dose aspirin differs from the response to&#xD;
           clopidogrel, a drug that interferes with platelet function downstream of the site of&#xD;
           aspirin action.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date>March 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retinal blood flow</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Retinal arterial blood speed</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal arterial diameter</measure>
  </secondary_outcome>
  <enrollment>100</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetic Retinopathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-45 years,&#xD;
&#xD;
          -  type 1 diabetes duration 1-15 years,&#xD;
&#xD;
          -  absent or minimal retinopathy (EDTRS 20).&#xD;
&#xD;
          -  Age- and gender-matched healthy controls&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  smoking,&#xD;
&#xD;
          -  systemic diseases other than diabetes,&#xD;
&#xD;
          -  retinal diseases other than diabetic retinopathy,&#xD;
&#xD;
          -  pregnancy,&#xD;
&#xD;
          -  bleeding disorders,&#xD;
&#xD;
          -  aspirin allergy,&#xD;
&#xD;
          -  use of anti-platelet agents,&#xD;
&#xD;
          -  non-steroidal anti-inflammatory agents,&#xD;
&#xD;
          -  angiotensin converting enzyme inhibitors,&#xD;
&#xD;
          -  angiotensin receptor antagonists,&#xD;
&#xD;
          -  Vitamin E in large doses.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mara Lorenzi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Schepens Eye Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Schepens Eye Research Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2006</verification_date>
  <study_first_submitted>November 30, 2006</study_first_submitted>
  <study_first_submitted_qc>December 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <last_update_submitted>October 28, 2015</last_update_submitted>
  <last_update_submitted_qc>October 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2015</last_update_posted>
  <keyword>retinal blood flow</keyword>
  <keyword>diabetic retinopathy</keyword>
  <keyword>microthrombosis</keyword>
  <keyword>aspirin</keyword>
  <keyword>clopidogrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

